semaglutide and cardiovascular outcomes in obesity without diabetes journal club VisualAbstract: Improves Patients with Obesity-Related Heart Failure Type 2 #VisualAbstract: Semaglutide and Cardiovascular Outcomes

The FDA update comes as the federal agency has received more than 6,100 reports of an array of gastrointestinal disorders from Ozempic users, including gastroparesis or stomach paralysis. The manufacturers of Ozempic and Mounjaro are being sued over claims that the companies downplayed the severity of the gastrointestinal events from using the drugs

Flying with tirzepatide Air travel introduces unique considerations

In the early stage of iron dependent death, ROS, particularly the accumulation of phospholipid hydroperoxides, play a critical role

Look for teachable moments during patient interactions, and use non-judgmental language to engage them

Taking it with food can also help reduce nausea or stomach discomfort

CoQ10 is primarily absorbed in the small intestine